The gross motor function measure™ is a valid and sensitive outcome measure for spinal muscular atrophy

Leslie Nelson, Hollis Owens, Linda S. Hynan, Susan T. Iannaccone, Group AmSMART Group

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Spinal muscular atrophy is a genetic disease of the anterior horn cell with high morbidity rate in childhood. Certain drugs may be of benefit and are in or under consideration for Phase II trials. Outcome measures that are age appropriate and representative of disease activity remain under study. Several have not yet been validated for spinal muscular atrophy. The Gross Motor Function Measure™ is a measure of motor function. We showed previously that the Gross Motor Function Measure™ is a reliable outcome measure to assess motor function in children with spinal muscular atrophy. By collating our data from 40 spinal muscular atrophy patients, ages 5 through 17 years, we now show the validity of the Gross Motor Function Measure™ when compared to Quantitative Muscle Testing and ambulatory status in children with spinal muscular atrophy. The median for Gross Motor Function Measure™ total scores for walkers was 237 (range: 197-261) and for non-walkers, 64 (range: 4-177; P<0.0001) with no distributional overlap. We conclude that the Gross Motor Function Measure™ is valid and sensitive as an outcome measure for clinical trials in pediatric spinal muscular atrophy.

Original languageEnglish (US)
Pages (from-to)374-380
Number of pages7
JournalNeuromuscular Disorders
Volume16
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Spinal Muscular Atrophy
Outcome Assessment (Health Care)
Walkers
Anterior Horn Cells
Inborn Genetic Diseases
Clinical Trials
Pediatrics
Morbidity
Muscles
Pharmaceutical Preparations

Keywords

  • Clinical trials
  • Gross motor function measure
  • Outcome measures
  • Quantitative muscle testing
  • Spinal muscular atrophy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

The gross motor function measure™ is a valid and sensitive outcome measure for spinal muscular atrophy. / Nelson, Leslie; Owens, Hollis; Hynan, Linda S.; Iannaccone, Susan T.; AmSMART Group, Group.

In: Neuromuscular Disorders, Vol. 16, No. 6, 06.2006, p. 374-380.

Research output: Contribution to journalArticle

@article{3c81b87ea4f04dc9810bed70a5958a84,
title = "The gross motor function measure™ is a valid and sensitive outcome measure for spinal muscular atrophy",
abstract = "Spinal muscular atrophy is a genetic disease of the anterior horn cell with high morbidity rate in childhood. Certain drugs may be of benefit and are in or under consideration for Phase II trials. Outcome measures that are age appropriate and representative of disease activity remain under study. Several have not yet been validated for spinal muscular atrophy. The Gross Motor Function Measure™ is a measure of motor function. We showed previously that the Gross Motor Function Measure™ is a reliable outcome measure to assess motor function in children with spinal muscular atrophy. By collating our data from 40 spinal muscular atrophy patients, ages 5 through 17 years, we now show the validity of the Gross Motor Function Measure™ when compared to Quantitative Muscle Testing and ambulatory status in children with spinal muscular atrophy. The median for Gross Motor Function Measure™ total scores for walkers was 237 (range: 197-261) and for non-walkers, 64 (range: 4-177; P<0.0001) with no distributional overlap. We conclude that the Gross Motor Function Measure™ is valid and sensitive as an outcome measure for clinical trials in pediatric spinal muscular atrophy.",
keywords = "Clinical trials, Gross motor function measure, Outcome measures, Quantitative muscle testing, Spinal muscular atrophy",
author = "Leslie Nelson and Hollis Owens and Hynan, {Linda S.} and Iannaccone, {Susan T.} and {AmSMART Group}, Group",
year = "2006",
month = "6",
doi = "10.1016/j.nmd.2006.03.005",
language = "English (US)",
volume = "16",
pages = "374--380",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - The gross motor function measure™ is a valid and sensitive outcome measure for spinal muscular atrophy

AU - Nelson, Leslie

AU - Owens, Hollis

AU - Hynan, Linda S.

AU - Iannaccone, Susan T.

AU - AmSMART Group, Group

PY - 2006/6

Y1 - 2006/6

N2 - Spinal muscular atrophy is a genetic disease of the anterior horn cell with high morbidity rate in childhood. Certain drugs may be of benefit and are in or under consideration for Phase II trials. Outcome measures that are age appropriate and representative of disease activity remain under study. Several have not yet been validated for spinal muscular atrophy. The Gross Motor Function Measure™ is a measure of motor function. We showed previously that the Gross Motor Function Measure™ is a reliable outcome measure to assess motor function in children with spinal muscular atrophy. By collating our data from 40 spinal muscular atrophy patients, ages 5 through 17 years, we now show the validity of the Gross Motor Function Measure™ when compared to Quantitative Muscle Testing and ambulatory status in children with spinal muscular atrophy. The median for Gross Motor Function Measure™ total scores for walkers was 237 (range: 197-261) and for non-walkers, 64 (range: 4-177; P<0.0001) with no distributional overlap. We conclude that the Gross Motor Function Measure™ is valid and sensitive as an outcome measure for clinical trials in pediatric spinal muscular atrophy.

AB - Spinal muscular atrophy is a genetic disease of the anterior horn cell with high morbidity rate in childhood. Certain drugs may be of benefit and are in or under consideration for Phase II trials. Outcome measures that are age appropriate and representative of disease activity remain under study. Several have not yet been validated for spinal muscular atrophy. The Gross Motor Function Measure™ is a measure of motor function. We showed previously that the Gross Motor Function Measure™ is a reliable outcome measure to assess motor function in children with spinal muscular atrophy. By collating our data from 40 spinal muscular atrophy patients, ages 5 through 17 years, we now show the validity of the Gross Motor Function Measure™ when compared to Quantitative Muscle Testing and ambulatory status in children with spinal muscular atrophy. The median for Gross Motor Function Measure™ total scores for walkers was 237 (range: 197-261) and for non-walkers, 64 (range: 4-177; P<0.0001) with no distributional overlap. We conclude that the Gross Motor Function Measure™ is valid and sensitive as an outcome measure for clinical trials in pediatric spinal muscular atrophy.

KW - Clinical trials

KW - Gross motor function measure

KW - Outcome measures

KW - Quantitative muscle testing

KW - Spinal muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=33745027696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745027696&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2006.03.005

DO - 10.1016/j.nmd.2006.03.005

M3 - Article

C2 - 16632361

AN - SCOPUS:33745027696

VL - 16

SP - 374

EP - 380

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 6

ER -